---
document_datetime: 2025-01-27 15:36:40
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sitagliptin-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sitagliptin-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.0480272
conversion_datetime: 2025-12-27 17:26:24.646177
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sitagliptin Accord

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0003/G            | This was an application for a group of variations. B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms B.II.e.1.a.1 - Change in immediate packaging of the | 24/01/2025                          |                                             | SmPC, Labelling and PL           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| finished product - Qualitative composition - Solid pharmaceutical B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.II.e.1.a.1 - Change in finished product - Qualitative   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.I.b.1.h - Change in the and/or limits of an AS, starting material/intermediate/reagent replacement (excl. Biol. specification parameter quality issue B.II.c.1.f - Change in the and/or limits of an excipient replacement (excluding product) of a specification corresponding test method quality issue B.II.c.1.f - Change in the and/or limits of an excipient replacement (excluding product) of a specification corresponding test method quality issue B.II.c.1.f - Change in the and/or limits of an excipient replacement (excluding product) of a specification   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | quality issue B.II.c.1.f - Change in the specification parameters and/or limits of an excipient - Addition or replacement (excluding biological or immunological product) of a specification parameter with its corresponding test method as a result of a safety or quality issue B.II.d.1.g - Change in the specification parameters and/or limits of the finished product - Addition or replacement (excluding biological or immunological product) of a specification parameter wit its corresponding test method as a result of a safety or quality issue B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale   |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0001/G | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                | 12/08/2022 | n/a |